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Background: Attempts to improve the tolerability of combined oral contraceptives (COCs) have included the substitution of ethinylestradiol
(EE) with 17β-estradiol (E2). However, this has proved unsatisfactory, specifically in terms of cycle control. To improve upon the poor cycle
control seen previously, E2 [in the form of estradiol valerate (E2V); 1 mg of E2V contains 0.76 mg of E2] was combined with dienogest
(DNG) in a novel four-phasic regimen. In the current studies, the ovulation-inhibition potency of four variations of this regimen was assessed.
Study Design: Two randomized, open-label, Phase II studies were performed. The first study compared two regimens (Regimens 1A and 2A)
with similar dosages of DNG but different lengths of application. Having established in Study 1 that the length of application of Regimen 2A
was most suitable, but that the dosages of DNG were too low for effective ovulation inhibition, a second study, which compared two
regimens (Regimens 2B and 2C) with similar lengths of application but with increased dosages of DNG, was undertaken. The primary
efficacy variable in both studies was the proportion of women with a Hoogland score of 5 or 6 during Cycle 2.
Results: The full analysis set comprised 192 and 203 women in Studies 1 and 2, respectively. In Study 1, 10 women (10.9%) in Regimen 1A
and 6 women (6.4%) in Regimen 2A had a Hoogland score of 5 or 6. In Study 2, three women (3.1%) in Regimen 2B and one woman (1.0%)
in Regimen 2C had a Hoogland score of 5 or 6. There were no safety concerns with any of the regimens.
Conclusion: The results of these studies identified a four-phasic COC preparation comprising E2V/DNG that provides efficient ovulation
inhibition. It is expected that this regimen will lead to an innovative COC containing E2 instead of EE.
© 2008 Elsevier Inc. All rights reserved.Keywords: Ovulation inhibition; Four-phasic regimen; Estradiol valerate; Dienogest☆ This study was supported by an unrestricted grant from Bayer
Schering Pharma AG (Berlin, Germany).
☆☆ Jan Endrikat, Susanne Parke, and Dietmar Trummer are employees
of Bayer Schering Pharma AG. Ingrid Duijkers and Christine Klipping are
employees of the Contract Research Organisation Dinox BV who were
contracted to perform the studies.
⁎ Corresponding author. Bayer, Inc., Toronto, Ontario, Ontario M9W
1G6, Canada. Tel.: +1 416 246 5033; fax: +1 416 248 9526.
E-mail address: jan.endrikat.b@bayer.com (J. Endrikat).
0010-7824/$ – see front matter © 2008 Elsevier Inc. All rights reserved.
doi:10.1016/j.contraception.2008.05.0041. Introduction
There have been several attempts in the past to increase the
tolerability of combined oral contraceptives (COCs). Such
initiatives have included introducing new progestins [1–3],
reducing the dose of ethinylestradiol (EE) [4–7] and
replacing EE with 17β-estradiol (E2) [8–19]. However,
previous attempts to replace EE with E2 proved somewhat
unsatisfactory with respect to cycle control [8,13,15–17],
particularly when E2 was administered as part of a mono-
phasic or a biphasic regimen.
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in previous studies of E2-containing COCs, a novel
preparation was developed in which E2 [in the form of
estradiol valerate (E2V); 1 mg of E2V contains 0.76 mg of
E2] was combined with dienogest (DNG) in a four-phasic
regimen [14,19]. DNG was included as the progestin
component, as it is known to have a particularly strong
endometrial effect [20]. A unique four-phasic regimen,
which incorporated an estrogen step-down and a progestin
step-up, was used to solve the problem of poor cycle control
observed with previous E2-containing COCs. Early estro-
genic dominance with the regimen ensured initial endome-
trial proliferation and sensitivity to midcyclic progestin
action, while the use of DNG, with its specific endometrial
affinity and dominance during the middle part to the late part
of the cycle, ensured endometrial stroma stability, particu-
larly towards the end of the cycle.
In the current studies, the ovulation-inhibition potency of
four variations of the four-phasic preparation of E2V and
DNG described above was assessed. The purpose of these
studies, which were performed in an iterative stepwise
manner, was to determine the optimal length of application
(Study 1) and the required dose of DNG (Study 2) for
effective inhibition of ovulation.2. Materials and methods
2.1. Study design
Two prospective, randomized, open-label studies were
performed at two centers: one in Germany (Clinical
Research, Dinox GmbH, Berlin, Germany) and another in
The Netherlands (Dinox Medical Investigations, Nijmegen,
The Netherlands). The two studies were performed in
sequence, with each study investigating two regimens. In
the first study, Regimens 1A and 2A, which comprised the
same dosages of DNG but different lengths of application,
were investigated. In the second study, having established
that the length of application of Regimen 2Awas suitable but
that the dosages of DNG were too low for effective ovulation
inhibition, Regimens 2B and 2C were investigated. Regi-
mens 2B and 2C comprised the same length of application as
Regimen 2A, but included distinctly increased dosages of
DNG. Fig. 1 shows each of the four regimens investigated
across the two studies. All regimens applied E2V in doses
decreasing from 3 mg to 1 mg. Since the valerate group of
E2V is split off during resorption and first-pass metabolism,
this results in a total E2 dosage of 0.764 mg per 1 mg of E2V
applied [21]. Previous research has shown that this is the
lowest effective estrogen dosage, and that further lowering of
the E2V dose results in reduced contraceptive efficacy (data
on file; Bayer Schering Pharma AG, Berlin, Germany).
Both studies were conducted in accordance with the
ethical principles of the Declaration of Helsinki and the
International Conference on Harmonization—Good Clinical
Practice Guidelines (January 17, 1997). The Ethics Commit-tees reviewed and gave their consent to the protocols before
the studies started. All women gave their informed consent
before participating in the study.
2.2. Subjects
Healthy women aged 18–35 years (smokers not older than
30 years) were eligible for inclusion in the studies. The
exclusion criteria were established based on contraindications
for COC use. Further exclusion criteria included specified
coexisting diseases, including metabolic and endocrine
diseases, diagnostically unclassified genital bleeding and a
history of liver or vascular diseases. In addition, women using
medications that could influence the study objectives, such as
sex steroids and drugs known to induce or inhibit liver
enzymes, were also excluded. Women had to be willing to use
nonhormonal contraceptive methods to protect themselves
from getting pregnant throughout the study. On screening, all
women underwent thorough medical and gynecological
examinations, including a cervical cytology examination
using the Papanicolaou method and a pregnancy test. Eligible
women underwent a pretreatment observation cycle (which
started on the first day of menstruation following screening),
and thosewho ovulated or had a follicular diameter of≥15mm
on or before Day 23 of the observation cycle, as assessed by
transvaginal ultrasound (TVU) examination (Siemens Sono-
line Siena GM 6600A2E00, transvaginal probe 6.5 EV13+
Convex Array Endo-V Probe or a Toshiba EccOcee model
SSA-340A), were randomized to treatment.
2.3. Study preparations
The study medications (produced by Bayer Schering
Pharma AG) were supplied in calendar packs. Treatment was
received in consecutive cycles of 28 days with no pill-free
interval. The treatment period was up to three cycles in Study
1 and also in Study 2. The first tablet was taken on the first
day of menstrual bleeding. The tablets were to be taken at
approximately the same time each day, with the interval
between two tablets as close as possible to 24 h. When the
scheduled tablet intake time was missed, the women had to
take the tablet as soon as they remembered, at the latest with
the next tablet. Tablet intake was recorded in a diary on a
daily basis.
Subjects were randomized to treatment in order of arrival
at the treatment center. Randomization was performed at
Bayer Schering Pharma AG using randomization blocks.
Randomization numbers were equally distributed between
the two treatment groups in each study.
2.4. Study assessments
2.4.1. Efficacy
Both studies were carried out to evaluate ovulation
inhibition, which was assessed by TVU monitoring of
follicle size and analysis of serum E2 and progesterone
levels, and classified according to the 6-point scoring
system of Hoogland and Skouby [22]. The primary efficacy
Fig. 1. Overview of four variations of a novel four-phasic COC containing E2V and DNG. Regimens 1A and 2A were initially investigated in Study 1, while
Regimens 2B and 2C were subsequently investigated in Study 2. The modifications from Regimen 1A to Regimens 2A, 2B and to 2C are highlighted.
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with a Hoogland score of 5 [luteinized unruptured follicle
(LUF)] or a Hoogland score of 6 (ovulation) at Cycle 2. A
Hoogland score of 6 is defined as a ruptured follicle-like
structure (FLS) of N13 mm with serum progesterone of N5
nmol/L and E2 of N0.1 nmol/L. A Hoogland score of 5 was
considered as critical as a Hoogland score of 6, since a
persisting FLS may still develop into a ruptured FLS in
subsequent cycles. Other efficacy end points assessed in
both studies included the proportion of women with a
Hoogland score of 5 or 6 at Cycle 3 and the proportion of
women with resumption of ovulation during the posttreat-
ment cycle.
TVU examinations and blood sampling for E2 and
progesterone were performed every third day (±1 day) in
both studies. In each cycle, the highest levels of hormonesand the greatest diameter of the follicle were used to
calculate the Hoogland score. The hormone assessments
were performed at a central laboratory in Germany
(Laboratory for Clinical Research, LKF GmbH, Raisdorf,
Germany) using assays based on the ElectroChemiLumi-
nescense ImmunoAssay technology on the analyzer Elecsys
(Roche Diagnostics GmbH, Mannheim, Germany).
In Study 1, TVU and hormone assessments were
performed during an untreated precycle and during two
treatment cycles. The precycle served to prove ovulation in
all subjects, while Cycles 1 and 2 comprised the regular
treatment cycles. Only those women with a nonpersisting
FLS of N13 mm (Hoogland score of 4) at the end of Cycle 2
were admitted to a third cycle of treatment in order to
monitor ‘stepwise’ follicular growth. At one study center, all
women not having a third cycle of treatment were monitored
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ovulation following treatment cessation.
Although the study procedures were identical in both
studies, the focus of Study 2 was modified according to
what was learned in Study 1. In Study 1, only Cycles 1 and
2 were intensively monitored, with Cycle 3 being assessed
only in those women who showed a nonpersisting FLS of
N13 mm at the end of Cycle 2. This resulted in a high
percentage of ovulations in Cycle 3. In order to clarify this
phenomenon, the focus of Study 2 was modified so as to
take data from Cycle 3 rather than from Cycle 1. As such,
all subjects received treatment for three cycles, and study
assessments were performed in the precycle and in Cycles
2 and 3, and not in Cycle 1. Similar to Study 1, one
posttreatment cycle was monitored at one study center in
Study 2 in order to assess the return of ovulation following
treatment cessation.
2.4.2. Safety
Safety was monitored by recording adverse events, body
weight, use of concomitant medications, treatment compli-
ance, and routine safety and laboratory parameters.
2.5. Statistical methods
It was planned to recruit 200 healthy women in each study
(100 women per treatment regimen). The sample size was
not based on any power calculation. However, an a posteriori
target was to reach an ovulation rate of b5%, with an upper
90% confidence limit of 10%. After observing Hoogland
scores of 5 or 6 in six women treated with Regimen 2A in
Study 1, it was expected that there would be up to four
women with Hoogland scores of 5 or 6 with Regimens 2B
and 2C in Study 2. Assuming a dropout rate of approxi-
mately 25%, it was necessary to include 100 subjects per
regimen into the study. All women who entered the studies
and who took at least one tablet of study medication and for
whom at least one observation after dosing was available
were included in the full analysis set (FAS).
All efficacy variables and demographic and baseline
variables were described according to their type, using
descriptive statistics.
The probability of a Hoogland score of 5 or 6 in Cycle 2
was estimated by the relative frequency of women with aTable 1
Demographic and baseline characteristics (FAS)
Study 1
Regimen 1A (n=96) Regim
Age (years) [mean±SD] 25.4±4.1 26.0±
Height (cm) [mean±SD] 167.8±6.2 168.4
Body weight (kg) [mean±SD] 63.6±9.9 64.5±
Body mass index (kg/m2) [mean±SD] 22.6±3.1 22.8±
Nullipara [n (%)] 77 (80.2) 72 (7
Prevalence of current smoking [n (%)] 34 (35.4) 35 (3
Oral contraceptive use before the start
of the study [n (%)]
43 (44.8) 39 (4Hoogland score of 5 or 6. Two-sided 90% confidence
intervals (CIs) were calculated for this probability for each
treatment and each cycle using normal approximations:
pˆTFu0:95
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
pˆT 1 pˆTð Þ
n
r
where subscript T denotes treatment, pˆT denotes the
estimated proportion and u0.95 denotes the 95% quantile of
the normal distribution. In addition, all Hoogland scores
were reported using descriptive statistics. All analyses were
conducted using SAS software (version 8).3. Results
3.1. Study population
In Study 1, a total of 236 women were screened, and 196
were randomized to treatment. Of these, 99 were assigned to
Regimen 1A, and 97 were assigned to Regimen 2A. The FAS
comprised 192 women (96 subjects in each of Regimens 1A
and 2A). For the primary efficacy variable, data for Cycle 2
were evaluated in 92 and 94 women treated with Regimens
1A and 2A, respectively. Thirty-one women with a
nonpersisting FLS of N13 mm at the end of Cycle 2 were
admitted to a third treatment cycle.
In Study 2, a total of 268 women were screened, and 210
were randomized to treatment. Of these, 104 were assigned
to Regimen 2B, and 106 were assigned to Regimen 2C. The
FAS comprised 203 women (100 subjects in Regimen 2B,
and 103 subjects in Regimen 2C). For the primary efficacy
variable, data for Cycle 2 were evaluated in 96 and 97
women treated with Regimens 2B and 2C, respectively.
The demographic and baseline characteristics were well
matched in both studies and in all four treatment groups
alike (Table 1).
3.2. Primary efficacy variable
In Study 1, 10 women (10.87%; CI=5.53 16.21%) treated
with Regimen 1A and six women (6.38%; CI=2.24–10.53%)
treated with Regimen 2A had a Hoogland score of 5 or 6 in
Cycle 2. In Study 2, three women (3.13%; CI=0.20–6.05%)
treated with Regimen 2B and one woman (1.03%; CI=0.00–Study 2
en 2A (n=96) Regimen 2B (n=100) Regimen 2C (n=103)
4.4 25.6±3.7 26.0±4.2
±6.4 169.3±6.5 167.7±6.9
7.8 63.9±7.4 62.5±9.8
2.7 22.3±2.9 22.2±2.8
5.0) 89 (89.0) 82 (79.6)
6.5) 33 (33.0) 35 (34.0)
0.6) 44 (44.0) 50 (48.5)
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5 or 6 in Cycle 2 (Fig. 2). One of the six women in Group 2A
with a Hoogland score of 5 or 6 had a LUF, while all others
showed ovulations (Table 2).
3.3. Other efficacy variables
Of the 31 women in Study 1 who were admitted to a third
treatment cycle, 8 of 15 women (53.3%) treated with
Regimen 1A and 5 of 16 women (31.3%) treated with
Regimen 2A had ovulations in Cycle 3. In Study 2, two
women (2.2%) treated with Regimen 2B and one subject
(1.05%) treated with Regimen 2C ovulated in Cycle 3.
Of the women assessed during a posttreatment cycle,
more than 80% resumed ovulation (Table 2).
3.4. Tolerability
No safety concerns were noted with any of the regimens,
and the majority of treatment-related adverse events were
typical of those occurring during COC use (Table 3).
One woman in Study 1 (Regimen 1A) had a serious
adverse event that was considered possibly treatment-
related (ovarian cyst). No deaths occurred during the
studies. Four women in Study 1 had adverse events
considered possibly related to treatment that resulted in
study discontinuation [Regimen 1A, n=2 (ovarian cyst,
breast pain); Regimen 2A, n=2 (edema, diarrhea)]. In
Study 2, eight women had treatment-related adverse events
that resulted in discontinuation of treatment [Regimen 2B,
n=5 (depression, headache, worsening acne, eye irritation,
furunculosis); Regimen 2C, n=3 (emotional lability (n=2),
headache)].Fig. 2. Ovulation inhibition in Cycle 2: the percentage of women with a Hooglan
investigated in Study 1, while Regimens 2B and 2C were subsequently investigat4. Discussion
The two prospective, randomized, Phase II studies
described here were performed to obtain information on
the ovulation-inhibition potency of four variations of a
novel four-phasic COC comprising E2V and DNG. The
studies were carried out in a stepwise manner in order to
determine, firstly, a suitable length of application (Study 1)
and, secondly, a suitable dose of DNG (Study 2) for
effective ovulation inhibition (Fig. 1). Each step increased
the ovulation-inhibition potency remarkably, with the
result that Regimen 2B was identified as the regimen
with the lowest effective dose of DNG for efficient
ovulation inhibition. This regimen — comprising 3 mg of
E2V for 2 days; 2 mg of E2V/2 mg of DNG for 5 days;
2 mg of E2V/3 mg of DNG for 17 days; 1 mg of E2V for
2 days; and placebo for 2 days — contained the lowest
dose of DNG that inhibited more than 95% of ovulations
in Cycle 2.
COCs typically exhibit Pearl Indices ranging between 0
and 1 (pregnancies per 100 women-years) in clinical studies.
Discrepancies between contraceptive efficacy in real-life
conditions and the results of classical Pearl Index studies
can, in part, be explained by the additional contraceptive
effects provided by hormonal contraceptives through altera-
tions in the cervical mucus and the endometrium [23]. Based
on the pharmacodynamic properties of DNG [20], such
extraovarian contraceptive effects are also expected with the
combination of E2V and DNG.
As mentioned previously, because monitoring of Cycle 3
was only performed in those women who showed a
nonpersisting FLS of N13 mm at the end of Cycle 2 ind score of 5 or 6 and 90% CIs (FAS). Regimens 1A and 2A were initially
ed in Study 2. LL, lower limit; UL, upper limit.
Table 2
Ovulation inhibition in Cycles 1–3 (FAS)
Hoogland score of 5 or 6 [n (%)] Study 1 Study 2
Regimen 1A (n=96) Regimen 2A (n=96) Regimen 2B Regimen 2C
Cycle 1
LUF 0 (0.0) 0 (0.0) ND ND
Ovulation 0 (0.0) 0 (0.0) ND ND
Hoogland score of 5 or 6 [n (%)] Study 1 Study 2
Regimen 1A (n=92) Regimen 2A (n=94) Regimen 2B (n=96) Regimen 2C (n=97)
Cycle 2 (see Fig. 2)
LUF 0 (0.0) 1 (1.1) 0 (0.0) 0 (0.0)
Ovulation 10 (10.9) 5 (5.3) 3 (3.1) 1 (1.0)
Hoogland score of 5 or 6 [n (%)] Study 1 Study 2
Regimen 1A (n=15) Regimen 2A (n=16) Regimen 2B (n=91) Regimen 2C (n=95)
Cycle 3
LUF 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Ovulation 8 (53.3) 5 (31.3) 2 (2.2) 1 (1.1)
Hoogland score of 5 or 6 [n (%)] Study 1 Study 2
Regimen 1A (n=35) Regimen 2A (n=40) Regimen 2B (n=39) Regimen 2C (n=44)
Posttreatment cycle
LUF 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Ovulation 30 (85.7) 39 (97.5) 33 (84.6) 36 (81.8)
ND=not done.
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women receiving a third cycle of treatment. As such, in
Study 2, all women were treated for three cycles, and data
were taken from Cycle 3 rather than from Cycle 1. A
comparison of ovarian activity in Study 2 showed no
difference between Cycles 2 and 3, consistent with previous
findings [24].
In both studies, it was decided to consider a Hoogland
score of 5 (LUF) to be as critical as a Hoogland score of 6
(ovulation), since the transition from a persisting FLS into a
ruptured FLS might happen easily in subsequent cycles, as
shown in Study 1. Spona et al. [25] administered a COC
containing 20 mcg of EE/100 mcg of levonorgestrel, andTable 3
Frequently reported adverse events (≥5% of subjects in any regimen)
considered to be (possibly/probably/definitely) related to treatment (FAS)
Adverse events
[n (%)]
Study 1 Study 2
Regimen 1A
(n=96)
Regimen 2A
(n=96)
Regimen 2B
(n=100)
Regimen 2C
(n=103)
Headache 16 (16.7) 13 (13.5) 18 (18.0) 25 (24.3)
Abdominal pain 12 (12.5) 12 (12.5) 12 (12.0) 11 (10.7)
Acne 7 (7.3) 7 (7.3) 9 (9.0) 14 (13.6)
Breast pain 6 (6.3) 10 (10.4) 6 (6.0) 10 (9.7)
Dysmenorrhea 6 (6.3) 4 (4.2) 10 (10.0) 9 (8.7)
Emotional
lability
5 (5.2) 1 (1.0) 7 (7.0) 10 (9.7)
Nausea 4 (4.2) 2 (2.1) 7 (7.0) 6 (5.8)reported one LUF per 24 subjects in Cycle 2 and one LUF
per 23 subjects in Cycle 3. This would have resulted in a
point estimation of 4.2% and a 90% CI of 0.0–10.9%. An
ovulation rate of b5% and an upper 90% CI of b10% were
defined in an effort to be ‘on the safe side’ before initiating a
Phase III clinical trial program. Regimen 2B reached this
target with the lowest dose of DNG, whereas Regimen 2C
reached a similar result but with a higher dose, which cannot
be justified.
Hirvonen et al. [12] tested biphasic formulations of E2V
plus either cyproterone acetate (CPA) or norethisterone
(NET) in a total of 50 ovulating women over a period of 1
year. In total, 1 ovulatory cycle was observed in those
women who received E2V/CPA (Cycle 1, n=1), compared
with 11 ovulatory cycles in those women who received E2V/
NET (Cycle 1, n=4; Cycle 2, n=2; Cycle 3, n=5). However,
it should be noted that women included in the study were
aged 35–47 years and, therefore, were not in the optimal
fertile age range. A follow-up study in 288 women showed
an ovulation-inhibition rate of 95%; however, the population
had a mean age of 39.3±3.4 years [11,13]. In addition,
Csemiczky et al. [18] tested a biphasic regimen with E2 and
desogestrel in 29 women with promising results in terms of
ovulation inhibition and cycle control. However, no further
data using this approach with bigger sample sizes have been
identified.
The basis for the work described here, specifically
Regimen 1A, was initially outlined by Hoffmann et al.
[14,19]. They carried out a pilot study in 100 healthy women
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control. Intermenstrual bleeding was recorded in 30% of
cycles during the first three cycles. However, further (so far
unpublished) data have revealed that ovulation inhibition
was unsatisfactory with such a regimen, which led to the
regimen modifications described in this article.
Currently available COCs have been proven to be safe
and well tolerated in most women. Nevertheless, several
attempts have been made to further improve the safety and
tolerability profile of COCs. E2 is considerably less potent
than EE in terms of hepatic protein synthesis induction, as
demonstrated in clinical studies assessing sex-hormone-
binding globulin, angiotensinogen and hemostatic para-
meters [26–29]. Such data suggest that a COC containing
E2V at dosages used in the current study would induce less
estrogen-related responses in the liver than currently
available EE-containing COCs. However, further clinical
and epidemiological studies will be needed to confirm
whether this translates into better clinical outcomes.
Numerous attempts to replace EE with E2 in COCs
have thus far been unsuccessful. In the studies described
here, it was demonstrated that a high degree of ovulation
inhibition can be achieved with a regimen containing E2V.
The safety data of these two studies did not raise any
concerns. The relatively high incidences of adverse events
(Table 3) are likely due to the Phase II design, as seen in
most studies of this type. Based on the findings of these
studies, Regimen 2B was identified as the lowest effective
dose for efficient suppression of ovulation. The cycle
control, safety and efficacy of this regimen are currently
being investigated in a Phase III clinical trial program. It is
expected that this preparation will be the first globally
available COC to use E2 instead of EE as the estrogen
component, providing reliable contraceptive efficacy and
acceptable cycle control.
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